Issue of Debt/BondGrünenthal announces pricing of €500 million bond 27.11.2024 / 09:35 CET/CESTThe issuer is solely ...

VICTORIA, BC / ACCESSWIRE / November 26, 2024 / AI/ML Innovations Inc. ("AI/ML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that that it has completed its previously ...

Disposal/Strategic Company DecisionMarinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals 27.11.2024 / 07:45 CET/CESTThe issuer is solely responsible ...

The CDC estimates approximately 385,000 needlestick and sharps-related injuries among U.S. healthcare workers each year BEAUMONT, TX / ACCESSWIRE / November 26, 2024 / Due to an alarming rise in ...

Renowned Facial Plastic Surgeon Dr. Rubinstein has been selected to train professionals on FDA-approved BOTOX® Cosmetic for neck rejuvenation in New Jersey.  MONTVALE, NJ / ACCESSWIRE / November 26, ...

Aston University and Women and Children’s Hospital developing new devices to improve drug treatment 26 November 2024 | Birmingham, UKThe new device is designed to reduce the risk of injuries when ...

ROCKVILLE, MD / ACCESSWIRE / November 26, 2024 / Dr. Roy Rubinfeld, an internationally renowned corneal surgeon and innovator, has developed a groundbreaking epithelium-on corneal cross-linking ...

Policy Recommendations to Reduce the Burden of COPD, calling for solutions to tackle the urgent challenge of chronic obstructive pulmonary disease (COPD), affecting 2% of the UK population, with many ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an ...

The former Clemson center, now with the Denver Nuggets, says ultrasound treatment with the sam® sustained acoustic medicine device from ZetrOZ Systems helps him recover faster and stay on the court.

NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite ...

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come ...